Varuni Kondagunta MDab Robert J Motzer MDab

aGenitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA hDepartment of Medicine, Joan and Sanford I. Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA

Almost all patients who have non-bulky stage II nonseminomatous germ cell tumors (NSGCT) can be cured with a cisplatin-based regimen following retroperitoneal lymph node dissection (RPLND). The study of adjuvant therapy in this clinical setting has included risk stratification of patients and a search for the most effective and least toxic chemotherapeutic regimen.

0 0

Post a comment